First Patient Enrolled in Toca 6, Tocagen’s Trial for Metastatic Cancers Evaluating Intravenously Delivered Toca 511 Virus

Study Investigates Potential Expansion Indications for Toca 511 & Toca FC SAN DIEGO – Sept. 22, 2016 – Tocagen, Inc., a clinical-stage, cancer-selective immunotherapy company, today announced the first patient has been enrolled in Toca 6, a Phase 1b study evaluating intravenously delivered Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release 5-fluorocytosine) in […]

RiboMed and Tocagen Announce Collaboration to Analyze Epigenetic Prognostic Markers

SAN DIEGO – July 6, 2016 – RiboMed Biotechnologies, Inc. and Tocagen Inc., today announced a collaboration to analyze potential epigenetic prognostic and predictive markers, including the gene for the DNA repair enzyme O-6-Methylguanine-DNA Methyltransferase (MGMT), in Tocagen’s clinical trials evaluating the investigational treatment Toca 511 & Toca FC in patients with recurrent high grade […]

Study Published in Science Translational Medicine Reports Favorable Safety and Extended Survival for Brain Cancer Patients Treated with Tocagen’s Cancer-Selective Viral Gene Therapy

SAN DIEGO – June 1, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced results from a multi-center study of an investigational immunotherapy, Toca 511 & Toca FC, have been published in the June 1, 2016, issue of Science Translational Medicine. The study, conducted in patients with recurrent brain cancer, showed extended […]

Tocagen Announces Presentations at the 2016 BIO International Convention and Boston CEO Conference

SAN DIEGO – May 26, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced members of the company’s management team will participate on a panel discussing the intersection of immuno, viral and gene-based therapies for cancer treatment and present a corporate overview at the 2016 BIO International Convention, to be held June […]

Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings

SAN DIEGO – May 13, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that results from the clinical investigation of Toca 511 & Toca FC for the treatment of recurrent high grade glioma will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June […]

Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting

Encouraging Survival, Proof of Mechanism, and Favorable Safety Was Demonstrated CHICAGO – May 3, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced positive clinical data involving intravenously delivered Toca 511 (vocimagene amiretrovepvec) in combination with Toca FC (extended-release flucytosine) for the treatment of recurrent high grade glioma were presented at the […]

Tocagen Presents Positive Preclinical, Proof-of-Mechanism Data at the American Association for Cancer Research (AACR) Annual Meeting

Combining Toca 511 and 5-FC with Checkpoint Inhibitors Reduces Tumor Burden in Preclinical Model Toca 511 and 5-FC Increased Survival in Preclinical Metastatic Colorectal Cancer Model NEW ORLEANS – April 19, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced positive preclinical, proof-of-mechanism data involving Toca 511 and 5-fluorocytosine (5-FC) were presented […]

Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences

SAN DIEGO – April 13, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that new results from the clinical investigation of Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine) for the treatment of recurrent high grade glioma will be presented at the 84th American Association of Neurological Surgeons (AANS) Annual Scientific […]

Tocagen to Present at Three Oncology Conferences

SAN DIEGO – March 17, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that members of the management team will present at the 9th Annual Oncology Commercialization & Market Access meeting, to be held March 22-23 in San Francisco; participate in a panel discussion at the Cancer Advance Boston conference, to […]

Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer to Canada

Patient Enrollment in the United States Ongoing SAN DIEGO – March 8, 2016 — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that its randomized, controlled Phase 2/3 clinical trial, called Toca 5, has expanded internationally and is now enrolling patients in Canada.

Tocagen Appoints John Wood as Vice President, Regulatory Affairs and Quality Assurance

SAN DIEGO – Feb. 16, 2016 — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that John Wood has been named vice president of regulatory affairs and quality assurance. Mr. Wood holds more than 20 years of regulatory affairs experience focusing on first-in-class drugs for diseases with high unmet need.

First Patient Enrolled in Toca 5, Tocagen’s Phase 2/3 Clinical Trial

SAN DIEGO – Dec. 3, 2015 — Tocagen Inc. a clinical-stage, cancer-selective immunotherapy company, today announced that the first patient has been enrolled in the Phase 2 portion of its randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC against current standard of care in patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection.

Tocagen Presents Updated Data at the SNO and SNO-SCIDOT Conferences

SAN DIEGO, – Nov. 23, 2015 – Tocagen Inc., a clinical-stage, cancer-selective immunotherapy company, today announced interim data from ongoing Phase 1 and preclinical studies of Toca 511 in combination with Toca FC were presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) and the SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS in San Antonio, TX.

Tocagen Announces Presentations at the SNO and SNO-SCIDOT Conferences

SAN DIEGO, – November 18, 2015 – Tocagen Inc., a clinical-stage, cancer-selective immunotherapy company, today announced that interim results from ongoing Phase 1 and preclinical studies of Toca 511 in combination with Toca FC will be presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), to be held Nov. 19-22, 2015, in San Antonio, TX.

Lori Kunkel, M.D., Joins Tocagen’s Board of Directors

SAN DIEGO, – Sept. 10, 2015 – Tocagen Inc., a clinical-stage immuno-oncology company, today announced that Lori Kunkel, M.D., has joined the company’s board of directors. Dr. Kunkel has more than twenty years of experience in oncology and immunology drug development and commercialization, including serving as chief medical officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals), which ultimately resulted in the global approvals of cancer therapeutics IMBRUVICA® and Kyprolis®, respectively.

Tocagen to Present at BioCentury’s NewsMakers in the Biotech Industry Conference

SAN DIEGO – Sept. 3, 2015 — Tocagen Inc., a clinical-stage immuno-oncology company, today announced the company will present at the BioCentury 22nd Annual NewsMakers in the Biotech Industry Conference. The presentation will take place on Thursday, Sept. 10, 2015 at 10:30 a.m. ET in room 508 of the Millennium Broadway Hotel in New York City.

FDA Grants Orphan Designation for Toca 511 & Toca FC

SAN DIEGO – Aug. 25, 2015 — Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company’s lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma.

FDA Grants Fast Track Designation to Tocagen’s Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma

SAN DIEGO – July 09, 2015 — Tocagen Inc. a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma.

Tocagen Appoints Asha Das, M.D, as Vice President Clinical Development and Medical Affairs

SAN DIEGO, – June 17, 2015 – Tocagen Inc., today announced Asha Das, M.D., has been named vice president of clinical development and medical affairs. Prior to joining Tocagen she held positions of increasing responsibility at Genentech, including leading activities related to the approval and launch of Avastin® in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to PD-L1.

Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors

SAN DIEGO – May 5, 2015 — Tocagen Inc. a clinical-stage immuno-oncology company, today announced that David R. Parkinson, M.D., a venture partner at New Enterprise Associates (NEA), has been appointed to the board of directors of Tocagen. Dr. Parkinson has more than twenty years of experience in oncology clinical development, including leading clinical activities at Amgen and Novartis that resulted in global approvals of the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® and Vectibix®, as well as serving as chief of the Investigational Drug Branch at the National Cancer Institute.

Tocagen Announces Updates from FDA Meeting and Clinical Data Presentations at AANS/CNS

WASHINGTON, D.C. – May 4, 2015 – Tocagen Inc. a clinical-stage immuno-oncology company, today announced updated interim data from Tocagen’s ongoing investigational studies were presented at the 11th Biennial Satellite Symposium of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors, held May 1-2, 2015, in Washington, D.C.

Tocagen Announces Presentations at the AANS/CNS Joint Section on Tumors

SAN DIEGO, – (April 30, 2015) — Tocagen Inc., a clinical-stage immuno-oncology company, today announced updated interim results from ongoing investigational studies of Toca 511 in combination with Toca FC will be presented by two principal investigators at the 11th Biennial Satellite Symposium of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors, to be held May 1-2, 2015, in Washington, D.C.

Tocagen Appoints Paul Schimmel, Ph.D, to the Board of Directors

SAN DIEGO, – February 25, 2015 – Tocagen Inc., a clinical-stage cancer-selective immunotherapy company, today announced that Paul Schimmel, Ph.D., Hahn professor of molecular biology and chemistry at The Scripps Research Institute, has been appointed to the board of directors.

Tocagen Appoints Franklin M. Berger, CFA, to the Board of Directors

SAN DIEGO – (December 2, 2014) — Tocagen Inc. a clinical-stage selective cancer immunotherapy company, today announced that Franklin M. Berger, CFA, has been appointed to the board of directors. Mr. Berger will also serve as the chairman of a newly formed audit committee responsible for overseeing Tocagen’s accounting, financial reporting, disclosure and financial risk management activities.

Toca 511 & Toca FC Survival and PFS-6 Data Surpasses Published Benchmarks

MIAMI – November 18, 2014 — Tocagen Inc. today announced that interim data showed increased median overall survival and progression free survival at six months for recurrent high grade glioma (HGG) patients treated with Toca 511 & Toca FC, compared to published benchmarks.

Tocagen Appoints Faheem Hasnain as Chairman of the Board of Directors

SAN DIEGO, – November 14, 2014 – Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced that Faheem Hasnain, president and chief executive officer of Receptos, Inc. (Nasdaq: RCPT), has been appointed as chairman of the board of directors.

Tocagen Announces Presentations at SNO 2014 Annual Conference

Tocagen to Present Toca 511 Data at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Tocagen Expands Clinical Development Team

SAN DIEGO, CA – August 26, 2014 – Tocagen Inc. today announced Wayne Saville, M.D., has been named vice president, clinical development, and Mary Rose Keller has been named vice president, clinical operations.

Tocagen Announces Presentations at ASGCT and ASCO Annual Conferences

SAN DIEGO – (May 22, 2014) — Tocagen Inc. today announced multiple scientific contributions at the American Society of Gene and Cell Therapy (ASGCT) 17th Annual Meeting, held May 21 to 24, 2014 at the Marriott Wardman Park in Washington, DC.

Tocagen Clinical Data Presented at AANS Annual Conference

SAN DIEGO, – (April 10, 2014) — Tocagen Inc. today announced that updated interim clinical data from two ongoing investigational studies of Toca 511 in combination with Toca FC in 68 patients with recurrent high grade glioma were presented at the American Association of Neurological Surgeons (AANS) Annual Meeting in San Francisco.

Tocagen Names Jamey Skillings, M.D., Chief Medical Officer

SAN DIEGO, – (March 25, 2014) — Tocagen Inc. today announced that Jamey Skillings, M.D., has been named Senior Vice President and Chief Medical Officer. Dr. Skillings joins Tocagen from Pfizer, where she was most recently vice president of global medical affairs for oncology.

Tocagen Announces Dosing of First Patient In Intravenous Study

SAN DIEGO, – (March 11, 2014) — Tocagen Inc. today announced that the first patient has been dosed in its clinical trial investigating the intravenous administration of selective cancer therapy Toca 511 & Toca FC, in patients with recurrent high grade glioma (HGG) including glioblastoma multiforme (GBM, Grade 4 HGG), the most common and aggressive form of primary brain cancer.